Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes

Table 4

Comparison changes in clinical parameters from baseline between different doses.

	One pill ()			Half a pill ()			value‡
	Baseline	36 months	value†	Baseline	36 months	value†
HbA1c, %	8.0 (7.4, 8.9)	7.0 (6.7, 7.9)	<0.001	7.8 (7.5, 9.4)	7.3 (6.9, 7.7)	<0.001	0.700
Body weight, kg	75 (64, 86)	73 (63, 82)	<0.001	74 (66, 78)	70 (65, 76)	0.001	0.098
SBP, mmHg	142 (131, 152)	132 (121, 139)	<0.001	144 (133,152)	131 (119, 141)	0.001	0.881
DBP, mmHg	82 (74, 89)	78 (70, 86)	0.007	77 (73, 88)	77 (67, 82)	0.029	0.946
FPG, mg/dL	165 (142, 184)	130 (116, 158)	<0.001	160 (131, 190)	128 (113, 155)	0.001	0.712
ALT, IU/L	29 (22, 41)	23 (19, 30)	<0.001	26 (19, 37)	23 (19, 39)	0.008	0.902
Scr, mg/dL	0.87 (0.66, 1.02)	0.88 (0.67, 1.06)	0.160	0.85 (0.65, 0.93)	0.80 (0.71, 0.97)	0.264	0.858
eGFR, mL/min/1.73 m^2	83 (69, 98)	84 (68, 104)	0.639	87 (74, 103)	82 (76, 97)	0.868	0.687
CHOL(T), mg/dL	153 (135, 178)	151 (129, 172)	0.436	165 (134, 177)	157 (136, 170)	0.247	0.631
Triglyceride, mg/dL	128 (97, 190)	112 (77, 177)	0.016	113 (96, 149)	99 (70, 137)	0.061	0.924
LDL-C, mg/dL	83 (69, 104)	82 (62, 97)	0.370	92 (72, 105)	83 (72, 102)	0.108	0.357
HDL-C, mg/dL	40 (34, 49)	42 (36, 51)	0.128	43 (36, 50)	47 (40, 54)	0.405	0.981

Data are shown as median (IQR). ALT: alanine aminotransferase; CHOT(T): total cholesterol; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein-cholesterol level; LDL-C: low-density lipoprotein-cholesterol level; SBP: systolic blood pressure; Scr: serum creatinine. †Wilcoxon sign rank test was used to compare of differences within groups measured at baseline and 36 months. ‡Mann–Whitney test was used to compare of differences between groups measured at baseline and 36 months. value <0.05 were considered statistically significant.